Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.

Abstract

BACKGROUND:

Pathologic complete response (pCR) to neoadjuvant chemotherapy (NCT) is considered a surrogate for improved survival. Platinum-containing NCT, particularly in patients with HER2+ and triple-negative breast cancers (TNBC) may increase pCR rates.

METHODS:

Tumor characteristics, pCR rates (no invasive disease in breast and lymph nodes), toxicities, and survival in patients who received carboplatin, a taxane, and trastuzumab (HER2+ disease) between April 2009 and December 2011, were reviewed.

RESULTS:

Thirty eight patients (39 tumors) completed a median of 4 cycles of NCT. Eighteen of 39 (46%) tumors were HER2+, 8/18 (44%) responded with pCR; 13/18 HER2+ tumors were HR+ (72%) and 4/13 (31%) had a pCR. Ten of 39 (26%) tumors were TNBC; 6/10 (60%) had a pCR. At a median of 25-months no recurrences were observed in patients with pCR.

CONCLUSIONS:

Prospective studies of anthracycline-free platinum-containing NCT are warranted in LABC patients with HER2+ and TNBC.

• Authors: Arvind M Shinde, Jing Zhai, Kim Wai Yu, Paul Frankel, John H Yim, Thehang Luu, Laura Kruper, Courtney Vito, Sally Shaw, Nayana L Vora, Michele Kirschenbaum, George Somlo
• Journal: Breast (Edinburgh, Scotland) (Breast) Vol. 24 Issue 1 Pg. 18-23 (Feb 2015) ISSN: 1532-3080 [Electronic] Netherlands
• PMID: 25467313 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2014 Elsevier Ltd. All rights reserved.

Chemical References

• Anthracyclines
• Antibodies, Monoclonal, Humanized
• Receptors, Estrogen
• Receptors, Progesterone
• Carboplatin
• ERBB2 protein, human
• Receptor, ErbB-2
• Trastuzumab
• Paclitaxel

Topics

• Adult
• Aged
• Anthracyclines (administration & dosage)
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Breast Neoplasms (drug therapy, pathology)
• Carboplatin (administration & dosage)
• Chemotherapy, Adjuvant
• Female
• Humans
• Middle Aged
• Neoadjuvant Therapy
• Neoplasm Recurrence, Local (drug therapy, pathology)
• Paclitaxel (administration & dosage)
• Receptor, ErbB-2
• Receptors, Estrogen
• Receptors, Progesterone
• Retrospective Studies
• Trastuzumab
• Triple Negative Breast Neoplasms (drug therapy, pathology)